Anika Therapeutics (ANIK) Non-Current Debt (2010 - 2020)

Anika Therapeutics (ANIK) reported Non-Current Debt of $25.0 million for Q3 2020, down 50.0% quarter-over-quarter from $50.0 million in Q2 2020.

Anika Therapeutics (ANIK) Non-Current Debt (2010 - 2020) Analysis & Trends

Anika Therapeutics (ANIK) has 5 years of Non-Current Debt data on file, last reported at $25.0 million in Q3 2020.

Non-Current Debt for Q3 2020 came in at $25.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2020 was $25.0 million (changed N/A YoY), and the FY2012 annual result was $8.0 million, down 16.67% from the prior year.
Non-Current Debt declined to $25.0 million in Q3 2020 per ANIK's latest filing, from $50.0 million in the prior quarter.
Over five years, Non-Current Debt peaked at $50.0 million in Q2 2020 and troughed at $25.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	14.02 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	9.05 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	3.92 Bn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	1.48 Bn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	569.60 Mn
10	Anika Therapeutics	197.89 Mn	131.10 Mn	19.00 Mn	-

Download Data